Key Statistics for ALGETA
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (NOK) (ttm)
|Est. EPS (NOK) (12/2013)
|Est. PEG Ratio
|Market Cap (M NOK)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ALGETA
- Net Income (M/NOK)
Algeta ASA operates in the pharmaceutical industry. The Company develops targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Algeta's compound Alpharadin is designed to treat bone metastases.
More Company Profile & Key Executives for ALGETA
|Andrew Martin KayPresident/CEO||Oystein SougChief Financial Officer|
|Thomas RamdahlChief Operating Officer||Roger HarrisonChief Business Officer|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.